These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 32595179)

  • 1. Increase of lymphocytes and eosinophils, and decrease of neutrophils at an early stage of anti-PD-1 antibody treatment is a favorable sign for advanced malignant melanoma.
    Ohashi H; Takeuchi S; Miyagaki T; Kadono T
    Drug Discov Ther; 2020 Jul; 14(3):117-121. PubMed ID: 32595179
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Investigation of clinical factors associated with longer overall survival in advanced melanoma patients treated with sequential ipilimumab.
    Muto Y; Kitano S; Tsutsumida A; Namikawa K; Takahashi A; Nakamura Y; Yamanaka T; Yamamoto N; Yamazaki N
    J Dermatol; 2019 Jun; 46(6):498-506. PubMed ID: 30945333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Complete responses to two different anti-PD1 agents in a metastatic melanoma patient.
    Kilickap S; Guven DC; Aktepe OH; Aktas BY; Dizdar O
    J Oncol Pharm Pract; 2020 Mar; 26(2):496-499. PubMed ID: 31256744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A phase II multicentre study of plasminogen activator inhibitor-1 inhibitor (TM5614) plus nivolumab for treating anti-programmed cell death 1 antibody-refractory malignant melanoma: TM5614-MM trial.
    Fujimura T; Yoshino K; Kato H; Fukushima S; Ishizuki S; Otsuka A; Matsushita S; Amagai R; Muto Y; Yamazaki E; Kambayashi Y; Yahata T; Miyata T; Fujisawa Y; Asano Y
    Br J Dermatol; 2024 Oct; 191(5):691-697. PubMed ID: 38833158
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum concentrations of HGF are correlated with response to anti-PD-1 antibody therapy in patients with metastatic melanoma.
    Kubo Y; Fukushima S; Inamori Y; Tsuruta M; Egashira S; Yamada-Kanazawa S; Nakahara S; Tokuzumi A; Miyashita A; Aoi J; Kajihara I; Tomita Y; Wakamatsu K; Jinnin M; Ihn H
    J Dermatol Sci; 2019 Jan; 93(1):33-40. PubMed ID: 30318169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ipilimumab alone or in combination with nivolumab after progression on anti-PD-1 therapy in advanced melanoma.
    Zimmer L; Apuri S; Eroglu Z; Kottschade LA; Forschner A; Gutzmer R; Schlaak M; Heinzerling L; Krackhardt AM; Loquai C; Markovic SN; Joseph RW; Markey K; Utikal JS; Weishaupt C; Goldinger SM; Sondak VK; Zager JS; Schadendorf D; Khushalani NI
    Eur J Cancer; 2017 Apr; 75():47-55. PubMed ID: 28214657
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic factors and outcomes in metastatic uveal melanoma treated with programmed cell death-1 or combined PD-1/cytotoxic T-lymphocyte antigen-4 inhibition.
    Heppt MV; Heinzerling L; Kähler KC; Forschner A; Kirchberger MC; Loquai C; Meissner M; Meier F; Terheyden P; Schell B; Herbst R; Göppner D; Kiecker F; Rafei-Shamsabadi D; Haferkamp S; Huber MA; Utikal J; Ziemer M; Bumeder I; Pfeiffer C; Schäd SG; Schmid-Tannwald C; Tietze JK; Eigentler TK; Berking C
    Eur J Cancer; 2017 Sep; 82():56-65. PubMed ID: 28648699
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab.
    Capone M; Giannarelli D; Mallardo D; Madonna G; Festino L; Grimaldi AM; Vanella V; Simeone E; Paone M; Palmieri G; Cavalcanti E; Caracò C; Ascierto PA
    J Immunother Cancer; 2018 Jul; 6(1):74. PubMed ID: 30012216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of Inflammatory Markers with Disease Progression in Patients with Metastatic Melanoma Treated with Immune Checkpoint Inhibitors.
    Pan M; Alavi M; Herrinton LJ
    Perm J; 2018; 22():17-149. PubMed ID: 29616914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.
    Jansen YJL; Rozeman EA; Mason R; Goldinger SM; Geukes Foppen MH; Hoejberg L; Schmidt H; van Thienen JV; Haanen JBAG; Tiainen L; Svane IM; Mäkelä S; Seremet T; Arance A; Dummer R; Bastholt L; Nyakas M; Straume O; Menzies AM; Long GV; Atkinson V; Blank CU; Neyns B
    Ann Oncol; 2019 Jul; 30(7):1154-1161. PubMed ID: 30923820
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
    Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
    J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
    [TBL] [Abstract][Full Text] [Related]  

  • 13. High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
    Bartlett EK; Flynn JR; Panageas KS; Ferraro RA; Sta Cruz JM; Postow MA; Coit DG; Ariyan CE
    Cancer; 2020 Jan; 126(1):76-85. PubMed ID: 31584709
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Peripheral PD-1+CD56+ T-cell frequencies correlate with outcome in stage IV melanoma under PD-1 blockade.
    Bochem J; Zelba H; Amaral T; Spreuer J; Soffel D; Eigentler T; Wagner NB; Uslu U; Terheyden P; Meier F; Garbe C; Pawelec G; Weide B; Wistuba-Hamprecht K
    PLoS One; 2019; 14(8):e0221301. PubMed ID: 31419253
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic role of neutrophil to lymphocyte ratio in advanced melanoma treated with anti-programmed death-1 therapy.
    Minowa T; Kato J; Hida T; Horimoto K; Sato S; Sawada M; Uhara H
    J Dermatol; 2018 Sep; 45(9):e250-e251. PubMed ID: 29572922
    [No Abstract]   [Full Text] [Related]  

  • 16. Correlation between blood cell count and outcome of melanoma patients treated with anti-PD-1 antibodies.
    Nakamura Y; Tanaka R; Maruyama H; Ishitsuka Y; Okiyama N; Watanabe R; Fujimoto M; Fujisawa Y
    Jpn J Clin Oncol; 2019 May; 49(5):431-437. PubMed ID: 30753621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dynamics of blood neutrophil-related indices during nivolumab treatment may be associated with response to salvage chemotherapy for non-small cell lung cancer: A hypothesis-generating study.
    Soda H; Ogawara D; Fukuda Y; Tomono H; Okuno D; Koga S; Taniguchi H; Yoshida M; Harada T; Umemura A; Yamaguchi H; Mukae H
    Thorac Cancer; 2019 Feb; 10(2):341-346. PubMed ID: 30582295
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Brief Communication on Circulating PD-1-positive T-Regulatory Lymphocytes in Melanoma Patients Undergoing Adjuvant Immunotherapy With Nivolumab.
    Gambichler T; Schröter U; Höxtermann S; Susok L; Stockfleth E; Becker JC
    J Immunother; 2019 Sep; 42(7):265-268. PubMed ID: 31145230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to the Rechallenge With Talimogene Laherparepvec (T-VEC) After Ipilimumab/Nivolumab Treatment in Patient With Cutaneous Malignant Melanoma Who Initially Had a Progression on T-VEC With Pembrolizumab.
    Afzal MZ; Shirai K
    J Immunother; 2019 May; 42(4):136-141. PubMed ID: 30933044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative-effectiveness of pembrolizumab vs. nivolumab for patients with metastatic melanoma.
    Moser JC; Wei G; Colonna SV; Grossmann KF; Patel S; Hyngstrom JR
    Acta Oncol; 2020 Apr; 59(4):434-437. PubMed ID: 31920132
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.